{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003515","form_type":"8-K","ticker":"ACTU","cik":"0001652935","company_name":"ACTUATE THERAPEUTICS, INC.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.670518+00:00","generated_at":"2026-05-14T22:46:28.285675+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Actuate Therapeutics appoints former Mersana CEO Martin Huber to board","bullets":["Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.","Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.","Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.","He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.","Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003515","json":"https://secwatch.observer/filing/0001683168-26-003515.json","markdown":"https://secwatch.observer/filing/0001683168-26-003515.md","text":"https://secwatch.observer/filing/0001683168-26-003515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/0001683168-26-003515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/actuate_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:46:28.285675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"540fd7eea9","claim":"Martin H. Huber was appointed as Class III Director at ACTUATE THERAPEUTICS, INC..","evidence_excerpt":"On May 1, 2026, the Board of Directors (\"Board\") of Actuate Therapeutics, Inc. (the \"Company\"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/0001683168-26-003515-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}